Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors

Clinical Cancer Research

Volumn 7, Issue 8, 2001, Pages 2573-2580

  Guilbaud, Nicolas ^a   Kraus Berthier, Laurence ^a   Meyer Losic, Florence ^a   Malivet, Virginie ^a   Chacun, Christine ^a   Jan, Michel ^a   Tillequin, Francois ^c   Michel, Sylvie ^c   Koch, Michel ^c   Pfeiffer, Bruno ^b   Atassi, Ghanem ^a   Hickman, John ^a   Pierré, Alain ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b ADIR   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACRONINE; ANTINEOPLASTIC AGENT; IRINOTECAN; NAVELBINE; PACLITAXEL; S 239061; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; LEUKEMIA; LEWIS CARCINOMA; LIVER METASTASIS; LUNG CANCER; LUNG METASTASIS; LYMPH NODE METASTASIS; MELANOMA; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

ACRONINE; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; FEMALE; HT29 CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, NUDE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034890518     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Alkaloids of the Australian Rutaceae
2. Alkaloids of Acronychia baueri. Isolation of the alkaloids and study of the antitumor and other biological properties of acronycine
3. Human tumor xenograft models in NCI drug development
4. Phase I-II evaluation of acronycine in patients with multiple myeloma
5. Development of a parenteral formulation for the anti-tumor agent acronycine
6. Antitumor activity and murine pharmacokinetics of parenteral acronycine
7. Synthesis and cytotoxic and antitumor activity of esters in the 1, 2-dihydroxy-l, 2-dihydroacronycine series
8. Synthesis and cytotoxic and antitumor activity of benzo[b]pyrano[3, 2-h]acridin-7-one analogues of acronycine
9. Cytotoxicity and cell cycle effect of S 23906, a new acronycine derivative
10. What is the optimal model for anti-tumor drug testing?
11. Biological and pharmacological characterization of three models of human ovarian carcinoma established in nude mice: Use of the CA 125 tumor marker to predict antitumor activity
12. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice
13. Orthotopic models are necessary to predict therapy of transplantable tumors in mice
14. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: A bridge to the clinic
15. In vivo antitumor activity of S 16020-2, a new olivacine derivative
16. Efficiency of orthotopic xenograft models for human colon cancers
17. Solutol HS 15 polyethylene glycol 660 hydroxystearate as nonionic solubilizer for injection solutions
18. Multicenter evaluation of the Elecsys CA 125 Assay
19. Protocols for screening chemical agents and natural products against tumors and others biological systems
20. Clinical applications of serum tumor markers
21. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
22. A Phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer
23. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
24. Oral chemotherapy: Rationale and future directions
25. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine